News | VIVA | October 05, 2020

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020

Top 10 trials listed below will be presented live

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions

October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical trials sessions during the virtual meeting Nov. 6-7, 2020. A multidisciplinary, international panel of expert physicians, scientists and regulators will ask questions and shed light on the lasting impact of the research results as they are presented for the first time. 

For more information: https://vivaphysicians.org/clinical-trials

Friday, Nov. 6, 
Session beginning at 11 a.m. PT

   • 5-Year Outcomes from the IN.PACT Global Study. Presented by Thomas Zeller, M.D., Ph.D.

   • Drug-Coated Devices & Limb Outcomes After Endovascular Peripheral Artery Revascularizations. Presented by Connie N. Hess, M.D., MHS.

   • Standard vs Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism. Presented by Efthymios Avgerinos, M.D., Ph.D., MSc.

   • VIVO Study 12-Month Endpoint Results. Presented by Anthony Comerota, M.D.

   • PROMISE I 1-Year Results. Presented by Daniel Clair, M.D.

Saturday, Nov. 7 
Session beginning at 7 a.m. PT

   • DISRUPT PAD III RCT Acute Results: IVL vs PTA in Severe Calcium. Presented by William A. Gray, M.D.

   • REALITY Study: Directional Atherectomy Vessel Preparation Prior to DCB Angioplasty. Presented by Krishna Rocha-Singh, M.D.

   • 24-Month Outcomes from the DETOUR 1 Trial for Percutaneous Femoropopliteal Bypass. Presented by Ehrin Armstrong, M.D.

   • 2-Year Outcomes of a Multi-Centre Study on Infrapopliteal Bioresorbable Vascular Scaffold. Presented by Steven Kum, M.D.

   • 4-Year DCB Mortality Across ILLUMENATE RCTs. Presented by Sean Lyden, M.D.

 

Related VIVA Conference Content:

VIVA 2019 Late-breaking Clinical Trials

Other VIVA news


Related Content

News | Cardiovascular Clinical Studies

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

Home September 28, 2023
Home
News | Cardiovascular Clinical Studies

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

Home September 19, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

Home September 14, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
Subscribe Now